糖尿病视网膜病变的个性化筛查策略:成本效果视角
研究基于荷兰Hoorn糖尿病护理系统队列5514例2型糖尿病患者的观察数据(1998-2017),利用经验证的风险预测模型确定个体化糖尿病视网膜病变筛查间隔,并与年度筛查和现行荷兰指南策略进行成本效果比较。结果显示个性化筛查模型比荷兰指南策略更具成本效果,虽及时诊断威胁视力的视网膜病变(STR)效果略逊于年度筛查,但延迟诊断数量低且节省费用可观。
要点
- 个性化筛查模型比荷兰指南策略更具成本效果,但每例患者费用略高(€1.8,医疗保健视角)。
- 在STR快速进展情景下,个性化筛查较年度筛查每例患者节省€11.4(医疗保健视角),但延迟STR诊断增加11.6%。
核心结论
- 个性化糖尿病视网膜病变筛查模型比荷兰指南筛查策略更具成本效果。
- 个性化筛查策略在及时诊断STR方面不如年度筛查有效,但延迟STR诊断数量低且节省费用可观。
研究设计与样本
- 利用经验证的风险预测模型为每个个体确定最优糖尿病视网膜病变筛查间隔。
- 使用Hoorn糖尿病护理系统队列1998-2017年2型糖尿病患者的观察数据(n=5514)。
- 采用慢速和快速STR进展两种情景对视网膜病变分级缺失值进行填补。
- 通过比较模型基于的筛查间隔与观察到的STR发生时间来确定延迟STR诊断的数量。
- 从医疗保健视角和社会视角计算成本,并比较不同筛查策略的结果与成本。
主要发现
- 在STR快速进展情景下,医疗保健视角下个性化筛查较年度筛查每例患者费用低€11.4,但延迟STR诊断多11.6%。
- 个性化筛查模型在及时诊断STR方面优于荷兰指南策略(延迟STR诊断少8.8%),但医疗保健视角下每例患者费用略高€1.8。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In this study we examined the cost-effectiveness of three different screening strategies for diabetic retinopathy: using a personalised adaptive model, annual screening (fixed intervals), and the current Dutch guideline (stratified based on previous retinopathy grade). METHODS: For each individual, optimal diabetic retinopathy screening intervals were determined, using a validated risk prediction model. Observational data (1998-2017) from the Hoorn Diabetes Care System cohort of people with type 2 diabetes were used (n = 5514). The missing values of retinopathy grades were imputed using two scenarios of slow and fast sight-threatening retinopathy (STR) progression. By comparing the model-based screening intervals to observed time to develop STR, the number of delayed STR diagnoses was determined. Costs were calculated using the healthcare perspective and the societal perspective. Finally, outcomes and costs were compared for the different screening strategies. RESULTS: For the fast STR progression scenario, personalised screening resulted in 11.6% more delayed STR diagnoses and €11.4 less costs per patient compared to annual screening from a healthcare perspective. The personalised screening model performed better in terms of timely diagnosis of STR (8.8% less delayed STR diagnosis) but it was slightly more expensive (€1.8 per patient from a healthcare perspective) than the Dutch guideline strategy. CONCLUSIONS/INTERPRETATION: The personalised diabetic retinopathy screening model is more cost-effective than the Dutch guideline screening strategy. Although the personalised screening strategy was less effective, in terms of timely diagnosis of STR patients, than annual screening, the number of delayed STR diagnoses is low and the cost saving is considerable. With around one million people with type 2 diabetes in the Netherlands, implementing this personalised model could save €11.4 million per year compared with annual screening, at the cost of 658 delayed STR diagnoses with a maximum delayed time to diagnosis of 48 months.
引用
- Emamipour S, van der Heijden AAWA, Nijpels G, et al. A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective. Diabetologia. 2020. PMID: 32734441. doi:10.1007/s00125-020-05239-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。